2023-509188-26-00已完成1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart DiseaseEUCTR2005-001671-35-GBMedImmune, Inc.1,235
进行中（未招募）
不适用
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease.EUCTR2007-002070-61-HUMedImmune, LLC800
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease.Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).MedDRA version: 9.0Level: PTClassification code 10061603Term: <Manually entered code. Term in E.1.1>EUCTR2007-002070-61-PLMedImmune, Inc.1,235
进行中（未招募）
不适用
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart DiseaseSerious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).MedDRA version: 7.0Level: PTClassification code 10061603EUCTR2005-001671-35-BEMedImmune, Inc.600
进行中（未招募）
不适用
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart DiseaseSerious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).MedDRA version: 7.0Level: PTClassification code 10061603EUCTR2005-001671-35-CZMedImmune, Inc.1,400